Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies.

Journal:
Annals of Internal Medicine
Published:
Affiliations:
6
Authors:
8
Institutions Authors Share
University of Pittsburgh Medical Center (UPMC), United States of America (USA)
5.500000
0.69
University of Pittsburgh (Pitt), United States of America (USA)
2.500000
0.31